BTVPUR AlSap 2-4

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

блютанг-virus серотипа-2 antigena, блютанг-virus серотипа-4 antigena

Available from:

Mérial

ATC code:

QI04AA02

INN (International Name):

inactivated adjuvanted vaccine against bluetongue virus serotype 2 and 4 infections

Therapeutic group:

ovca

Therapeutic area:

virus блютанга, инактивированной virusna cjepiva, imunomodulatori za ovidae

Therapeutic indications:

Aktivna imunizacija ovaca radi sprječavanja viremije i smanjenja kliničkih znakova uzrokovanih serotipovima 2 i 4 virusa bolesti plavog jezika.

Product summary:

Revision: 4

Authorization status:

povučen

Authorization date:

2010-11-04

Patient Information leaflet

                                19
B. UPUTA O VMP
Lijek koji više nije odobren
20
UPUTA O VMP:
BTVPUR ALSAP 2-4 SUSPENZIJA ZA INJEKCIJU ZA OVCE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
MERIAL
29 avenue Tony Garnier
69007 Lyon
Francuska
Nositelj odobrenja za proizvodnju za puštanje proizvodne serije:
MERIAL
Laboratory od Lyon Porte des Alpes
Rue de l'Aviation,
69800 Saint-Priest
Francuska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
BTVPUR AlSap 2-4 suspenzija za injekciju za ovce.
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Svaka doza od 1 ml cjepiva sadrži:
Virusni antigen protiv bolesti plavog jezika serotip 2
................................................. 6,8 – 9,5 CCID
50
*
Virusni antigen protiv bolesti plavog jezika serotip 4
.................................................. 7,1 – 8,5 CCID
50
*
aluminijev hidroksid
2,7 mg
saponin
30 HU**
*Infektivna doza stanične kulture 50% jednako titru prije
inaktivacije (log
10
).
**Hemolitičke jedinice.
4.
INDIKACIJE
Aktivna imunizacija ovaca za sprječavanje viremije* i za smanjenje
kliničkih znakova uzrokovanih
virusom bolesti plavog jezika serotip 2 i 4.
*vrijednosti ispod razine otkrivanja validiranom RT-PCR metodom na
3,68 log
10
RNA copies/ml,
ukazuje na odsutnost virusa zaraze.
Početak imuniteta javio se 3 i 5 tjedna nakon prvog cijepljenja za
serotip 4 odnosno serotip 2.
Trajnost imuniteta je 1 godina nakon prvog cijepljenja.
5.
KONTRAINDIKACIJE
Nema.
Lijek koji više nije odobren
21
6.
NUSPOJAVE
Nakon cijepljenja se može na mjestu uboda javiti prolazni mali otok
(najviše 24 cm²) koji se povlači
za 14 dana.
Prolazno povišenje tjelesne temperature, obično ne više od 1,1 °C,
može se javiti unutar 24 sata nakon
cijepljenja.
Ako zamijetite ozbiljne nuspojave ili druge nuspojave koje nisu
opisane u uputi o VMP, molimo da se
javite veterinaru.
7.
CILJNE VRSTE ŽIVOTINJA
Ovce.
8.
DOZIRANJE ZA SVAKU CILJNU VRSTU
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
Lijek koji više nije odobren
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
BTVPUR AlSap 2-4 suspenzija za injekciju za ovce
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza od 1 ml cjepiva sadrži:
DJELATNE TVARI:
Virusni antigen protiv bolesti plavog jezika serotip 2
.................................................. 6,8 – 9,5 CCID
50
*
Virusni antigen protiv bolesti plavog jezika serotip 4
.................................................. 7,1 – 8,5 CCID
50
*
(*)
Infektivna doza stanične kulture 50% jednaka titru prije inaktivacije
(log
10
)
ADJUVANS:
Aluminijev hidroksid
2,7 mg
Saponin
30 HU**
**Hemolitičke jedinice
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Injekcijska suspenzija.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Ovce.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Aktivna imunizacija ovaca za sprječavanje viremije* i za smanjenje
kliničkih znakova uzrokovanih
virusom bolesti plavog jezika serotip 2 i 4.
*(vrijednosti ispod razine otkrivanja validiranom RT-PCR metodom na
3,68 log
10
RNA copies/ml,
ukazuje na odsutnost virusa zaraze)
Početak imuniteta javio se 3 i 5 tjedna nakon prvog cijepljenja za
serotip 4 odnosno serotip 2.
Trajnost imuniteta je 1 godina nakon prvog cijepljenja.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Ako se primjenjuje na druge domaće i divlje preživače za koje se
smatra da postoji opasnost od
zaraze, za te vrste treba upotrijebiti s oprezom, a preporučuje se i
testiranje cjepiva na malom broju
životinja prije masovnog cijepljenja. Razina djelotvornosti kod
drugih vrsta može se razlikovati od
one kod ovaca.
Lijek koji više nije odobren
3
4.5
POSEBNE MJERE OPREZA ZA PRIMJENU
Posebne mjere opreza za primjenu na životinjama
Cijepiti samo zdrave životinje.
Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje
veterinarsko-medicinski proizvod
na životinjama
Nije primjenjivo.
4.6
NUSPOJAVE (UČESTALOST I OZBILJNOST)
Nako
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-11-2018
Public Assessment Report Public Assessment Report Bulgarian 13-11-2018
Patient Information leaflet Patient Information leaflet Spanish 13-11-2018
Public Assessment Report Public Assessment Report Spanish 13-11-2018
Patient Information leaflet Patient Information leaflet Czech 13-11-2018
Public Assessment Report Public Assessment Report Czech 13-11-2018
Patient Information leaflet Patient Information leaflet Danish 13-11-2018
Public Assessment Report Public Assessment Report Danish 13-11-2018
Patient Information leaflet Patient Information leaflet German 13-11-2018
Public Assessment Report Public Assessment Report German 13-11-2018
Patient Information leaflet Patient Information leaflet Estonian 13-11-2018
Public Assessment Report Public Assessment Report Estonian 13-11-2018
Patient Information leaflet Patient Information leaflet Greek 13-11-2018
Public Assessment Report Public Assessment Report Greek 13-11-2018
Patient Information leaflet Patient Information leaflet English 13-11-2018
Public Assessment Report Public Assessment Report English 13-11-2018
Patient Information leaflet Patient Information leaflet French 13-11-2018
Public Assessment Report Public Assessment Report French 13-11-2018
Patient Information leaflet Patient Information leaflet Italian 13-11-2018
Public Assessment Report Public Assessment Report Italian 13-11-2018
Patient Information leaflet Patient Information leaflet Latvian 13-11-2018
Public Assessment Report Public Assessment Report Latvian 13-11-2018
Patient Information leaflet Patient Information leaflet Lithuanian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-11-2018
Public Assessment Report Public Assessment Report Lithuanian 13-11-2018
Patient Information leaflet Patient Information leaflet Hungarian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 13-11-2018
Public Assessment Report Public Assessment Report Hungarian 13-11-2018
Patient Information leaflet Patient Information leaflet Maltese 13-11-2018
Public Assessment Report Public Assessment Report Maltese 13-11-2018
Patient Information leaflet Patient Information leaflet Dutch 13-11-2018
Public Assessment Report Public Assessment Report Dutch 13-11-2018
Patient Information leaflet Patient Information leaflet Polish 13-11-2018
Public Assessment Report Public Assessment Report Polish 13-11-2018
Patient Information leaflet Patient Information leaflet Portuguese 13-11-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 13-11-2018
Public Assessment Report Public Assessment Report Portuguese 13-11-2018
Patient Information leaflet Patient Information leaflet Romanian 13-11-2018
Public Assessment Report Public Assessment Report Romanian 13-11-2018
Patient Information leaflet Patient Information leaflet Slovak 13-11-2018
Public Assessment Report Public Assessment Report Slovak 13-11-2018
Patient Information leaflet Patient Information leaflet Slovenian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 13-11-2018
Public Assessment Report Public Assessment Report Slovenian 13-11-2018
Patient Information leaflet Patient Information leaflet Finnish 13-11-2018
Public Assessment Report Public Assessment Report Finnish 13-11-2018
Patient Information leaflet Patient Information leaflet Swedish 13-11-2018
Public Assessment Report Public Assessment Report Swedish 13-11-2018
Patient Information leaflet Patient Information leaflet Norwegian 13-11-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 13-11-2018
Patient Information leaflet Patient Information leaflet Icelandic 13-11-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 13-11-2018